Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 4 | 2016 | 11 | 1.810 |
Why?
|
| Kidney Transplantation | 5 | 2026 | 22 | 1.550 |
Why?
|
| Organ Transplantation | 3 | 2022 | 14 | 1.450 |
Why?
|
| HIV Infections | 6 | 2026 | 135 | 1.350 |
Why?
|
| Graft Rejection | 5 | 2026 | 13 | 1.340 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 7 | 0.920 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 30 | 0.810 |
Why?
|
| Transplant Recipients | 3 | 2022 | 6 | 0.760 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 3 | 0.750 |
Why?
|
| Antimicrobial Stewardship | 1 | 2022 | 11 | 0.740 |
Why?
|
| Humans | 21 | 2026 | 5837 | 0.740 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 26 | 0.690 |
Why?
|
| Retrospective Studies | 8 | 2021 | 584 | 0.680 |
Why?
|
| Antifungal Agents | 2 | 2018 | 6 | 0.650 |
Why?
|
| Liver Transplantation | 2 | 2021 | 9 | 0.620 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 17 | 0.600 |
Why?
|
| Adult | 9 | 2026 | 1670 | 0.600 |
Why?
|
| Tissue Donors | 5 | 2026 | 28 | 0.570 |
Why?
|
| Middle Aged | 9 | 2026 | 1775 | 0.550 |
Why?
|
| Cryptococcosis | 1 | 2018 | 2 | 0.540 |
Why?
|
| Population Health | 1 | 2018 | 2 | 0.540 |
Why?
|
| Dermatomycoses | 1 | 2017 | 1 | 0.510 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.510 |
Why?
|
| Yeasts | 1 | 2017 | 1 | 0.510 |
Why?
|
| Fungemia | 1 | 2017 | 1 | 0.510 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 2 | 0.510 |
Why?
|
| Exanthema | 1 | 2017 | 5 | 0.510 |
Why?
|
| Male | 11 | 2026 | 3399 | 0.510 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.500 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 2 | 0.500 |
Why?
|
| Bacteremia | 1 | 2016 | 13 | 0.490 |
Why?
|
| Roseolovirus Infections | 1 | 2016 | 1 | 0.490 |
Why?
|
| Inpatients | 1 | 2015 | 19 | 0.450 |
Why?
|
| Liver Failure | 1 | 2015 | 2 | 0.450 |
Why?
|
| Patient Readmission | 1 | 2015 | 21 | 0.440 |
Why?
|
| Heart Transplantation | 1 | 2014 | 5 | 0.440 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 4 | 0.440 |
Why?
|
| Female | 9 | 2026 | 3346 | 0.400 |
Why?
|
| United States | 5 | 2022 | 502 | 0.400 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 12 | 0.370 |
Why?
|
| Aged | 5 | 2021 | 1860 | 0.360 |
Why?
|
| Young Adult | 4 | 2021 | 421 | 0.340 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.340 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 21 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 109 | 0.280 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 187 | 0.280 |
Why?
|
| Cohort Studies | 3 | 2022 | 406 | 0.250 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 12 | 0.250 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 1034 | 0.240 |
Why?
|
| Risk Factors | 3 | 2021 | 499 | 0.230 |
Why?
|
| Trees | 1 | 2025 | 3 | 0.230 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 22 | 0.220 |
Why?
|
| Cytomegalovirus | 2 | 2015 | 3 | 0.220 |
Why?
|
| Asthma | 1 | 2025 | 35 | 0.220 |
Why?
|
| Time Factors | 2 | 2015 | 374 | 0.200 |
Why?
|
| HIV-1 | 1 | 2022 | 74 | 0.180 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 11 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2021 | 7 | 0.180 |
Why?
|
| Biomarkers | 1 | 2022 | 141 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 23 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 28 | 0.170 |
Why?
|
| Adolescent | 2 | 2025 | 488 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 54 | 0.170 |
Why?
|
| Rectal Prolapse | 1 | 2021 | 1 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 1 | 0.170 |
Why?
|
| Models, Biological | 1 | 2021 | 132 | 0.160 |
Why?
|
| Hospitalization | 1 | 2021 | 86 | 0.160 |
Why?
|
| Laparoscopy | 1 | 2021 | 47 | 0.160 |
Why?
|
| Comorbidity | 2 | 2021 | 98 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 333 | 0.140 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 1 | 0.140 |
Why?
|
| Cryptococcus | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cytarabine | 1 | 2017 | 1 | 0.130 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.130 |
Why?
|
| Trichosporon | 1 | 2017 | 1 | 0.130 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 1 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 1 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2017 | 1 | 0.130 |
Why?
|
| Echinocandins | 1 | 2017 | 2 | 0.130 |
Why?
|
| Amphotericin B | 1 | 2017 | 2 | 0.130 |
Why?
|
| Vidarabine | 1 | 2017 | 2 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2017 | 6 | 0.130 |
Why?
|
| Voriconazole | 1 | 2017 | 2 | 0.130 |
Why?
|
| Fever | 1 | 2017 | 14 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 37 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 35 | 0.120 |
Why?
|
| Paecilomyces | 1 | 2016 | 1 | 0.120 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 3 | 0.120 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 1 | 0.120 |
Why?
|
| Herpesvirus 7, Human | 1 | 2016 | 1 | 0.120 |
Why?
|
| Ganciclovir | 1 | 2016 | 4 | 0.120 |
Why?
|
| Dyspnea | 1 | 2016 | 14 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 34 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2016 | 13 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 53 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 71 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2015 | 30 | 0.110 |
Why?
|
| Incidence | 1 | 2014 | 165 | 0.100 |
Why?
|
| Graft Survival | 2 | 2024 | 21 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2026 | 411 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 1 | 0.080 |
Why?
|
| Molecular Typing | 1 | 2011 | 2 | 0.080 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 3 | 0.080 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 29 | 0.080 |
Why?
|
| Genotype | 1 | 2011 | 114 | 0.080 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Shellfish | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2026 | 11 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 67 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2025 | 43 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2025 | 174 | 0.050 |
Why?
|
| Disease Progression | 1 | 2025 | 157 | 0.050 |
Why?
|
| Chicago | 1 | 2025 | 239 | 0.050 |
Why?
|
| Child | 1 | 2025 | 339 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2024 | 154 | 0.050 |
Why?
|
| Proviruses | 1 | 2022 | 1 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 6 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 6 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2022 | 1 | 0.050 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2022 | 1 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2021 | 94 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 46 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 11 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 30 | 0.040 |
Why?
|
| Perineum | 1 | 2021 | 2 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 63 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 44 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2021 | 601 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 7 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 2 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 14 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 6 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 150 | 0.030 |
Why?
|
| Food Contamination | 1 | 2009 | 1 | 0.020 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 2 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 2 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 4 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 6 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 62 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 1349 | 0.010 |
Why?
|